Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Varex Imaging Corporation (VREX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded Nasdaq issuer. Varex designs and manufactures X-ray imaging components and systems for medical, industrial, and security applications, and its filings offer detailed insight into how this business is reflected in its financial statements, risk factors, and governance disclosures.
Through this page, users can review Varex’s periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present segment information for the Medical and Industrial businesses, revenue composition, gross margin, operating expenses including research and development, and details on capital structure items like long-term debt and convertible notes. These filings also contain management’s discussion and analysis and other disclosures that complement the high-level figures in press releases.
Current reports on Form 8-K document specific material events. For example, a recent 8-K furnished an earnings press release titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” while another 8-K described a transition agreement with the company’s Senior Vice President, Chief Legal Officer, and Corporate Secretary, outlining continued service, compensation, and equity vesting terms. Such filings help investors track both financial performance and key governance changes.
On Stock Titan, VREX filings are updated as they are made available through EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand topics such as segment performance, non-GAAP reconciliations, debt and liquidity, and executive arrangements. Users can also review ownership and insider activity through forms that report transactions by officers and directors, providing an additional perspective on Varex Imaging Corporation’s regulatory record.
Varex Imaging Corp director Christine A. Tsingos received an equity grant of 12,331 deferred stock units on February 12, 2026. The units were awarded at a price of $0 and are held directly. Each deferred stock unit converts into one share of Varex common stock.
The deferred stock units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to the director on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corp director Timothy E. Guertin reported an award of deferred stock units. On February 12, 2026, he acquired 12,331 Deferred Stock Units at a price of $0, all held directly.
Each unit converts into one share of common stock. The units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholders’ meeting. Vested shares will be delivered on the earlier of the third anniversary of the grant date, a change in control, or Guertin’s termination of service.
Varex Imaging Corp director Jocelyn D. Chertoff received an equity award in the form of deferred stock units. On 02/12/2026, she was granted 12,331 Deferred Stock Units at a price of $0. Each unit converts into one share of common stock.
The Deferred Stock Units vest 100% on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders after the grant. Vested shares will be delivered to her on the earlier of the third anniversary of the grant date, a change in control, or her termination of service.
Varex Imaging Corporation reported higher revenue and a small profit for the quarter ended January 2, 2026. Net revenues rose to $209.6M from $199.8M, and net income attributable to Varex improved to $2.3M, or $0.05 per diluted share, compared with a small loss a year earlier.
Industrial revenue grew to $64.8M from $55.2M, while Medical revenue was essentially flat at about $144.8M. Operating income increased to $15.4M, but interest and other expense of $11.6M (including a $3.2M equity-method loss from dpiX Holding) limited bottom-line growth.
Cash flow from operating activities was a use of $16.1M, driven largely by a $30.1M inventory build to $328.0M. Cash and cash equivalents declined to $119.5M, while Senior Secured Notes outstanding remained at $368.0M. The $155.0M revolving credit facility was undrawn, with $154.8M available. After quarter-end, Varex committed about $7.3M over three years for new manufacturing equipment.
Varex Imaging Corporation reported a solid first quarter of fiscal 2026 with year-over-year growth and improved profitability. Revenue reached $209.6 million, up 5% from $199.8 million a year earlier, driven by a 17% year-over-year increase in Industrial segment revenue to $64.8 million, while Medical revenue was stable at $144.8 million.
GAAP net income attributable to Varex improved to $2.3 million, or $0.05 per diluted share, from a loss of $0.3 million, or $(0.01) per diluted share, in the prior-year quarter. Non-GAAP diluted net income per share increased to $0.19 from $0.10, and non-GAAP operating margin rose to 9.0%. Adjusted EBITDA grew to $28.5 million from $25.5 million.
Operating cash flow was a $16 million outflow, and cash, cash equivalents, and marketable securities declined to $125.6 million at quarter-end from $155.1 million at the end of fiscal 2025, primarily due to higher inventories. For the second quarter of fiscal 2026, the company expects revenue between $210 million and $225 million and non-GAAP net earnings per diluted share between $0.15 and $0.25.
Varex Imaging Corp director Jay K. Kunkel reported a routine equity award settlement. On February 9, 2026, he converted 8,483 Deferred Stock Units into 8,483 shares of common stock at a price of $0 per share, reflecting previously granted director compensation.
The Deferred Stock Units were granted on February 9, 2023, vested on February 8, 2024, and were delivered in common stock on the third anniversary of the grant date. Following this settlement, Kunkel directly holds 27,960 shares of Varex Imaging Corp common stock.
Varex Imaging Corp director Jocelyn D. Chertoff reported the conversion of 8,483 Deferred Stock Units into 8,483 shares of common stock on February 9, 2026, at an exercise price of $0 per unit.
The footnotes state these Deferred Stock Units were granted on February 9, 2023, vested on February 8, 2024, and were delivered in stock on the third anniversary of the grant date. Following this settlement, Chertoff directly holds 42,194 shares of Varex Imaging common stock and no remaining Deferred Stock Units from this grant.
Varex Imaging Corp director Walter M. Rosebrough Jr. reported the conversion of 10,339 Deferred Stock Units into an equal number of Varex common shares on February 9, 2026. These units were originally granted on February 9, 2023 and became deliverable on the third anniversary of the grant date.
After this settlement, Rosebrough directly beneficially owns 52,654 shares of common stock. The Form 4 shows a routine equity compensation event with no cash consideration, as both the derivative units and the resulting common shares are reported at a transaction price of $0 per share.
Varex Imaging director Timothy E. Guertin converted deferred stock units into common shares. On February 9, 2026, 8,483 Deferred Stock Units were exercised and delivered as 8,483 shares of Varex Imaging common stock, consistent with a one-for-one conversion ratio.
These Deferred Stock Units were originally granted on February 9, 2023, vested on February 8, 2024, and were settled in stock on the third anniversary of the grant date. After this transaction, Guertin directly holds 26,777 shares of Varex Imaging common stock.
Varex Imaging Corp. director Kathleen Bardwell reported the conversion of equity awards into common stock. On February 9, 2026, she converted 8,483 Deferred Stock Units into 8,483 shares of common stock at an exercise price of $0 per share.
The filing shows this equity award delivery increased her directly held common stock to 12,102 shares after the transaction. Each Deferred Stock Unit converts into one share of common stock, reflecting previously granted and vested director compensation rather than an open-market purchase or sale.